← Leaderboards
Varghese John
Buck Institute For Research On Aging
$11,000,502
Attributed
$11,000,502
Total exposure
10
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.7M · FY2012–25$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,000,502 · 10
By mechanism
R01$6,535,531 · 4
R21$2,373,103 · 5
RF1$2,091,868 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseBrainNeuronsCellsMouse ModelEvaluationAmyloid Beta-ProteinDosePharmaceutical PreparationsPermeabilityIn VitroDrug KineticsScreeningS Disease ModelIn VivoPropertyReportingOralAffectLibrariesAnalogMemoryImpaired Cognition
Grant awards (24)
Optimization and preclinical evaluation of brain permeant SE-CRISPR to edit ApoE4 after IV infusion in AD models$751,442
R01 · FY2025 · AG · contact PI
Small molecule mimetics of Humanin that normalize neuronal p-Akt as novel therapeutics for AD$637,164
R01 · FY2025 · AG · contact PI
Evaluating the p-Tau inhibition and neuroprotective effects of sAPPalpha using brain permeable small molecules$382,200
R01 · FY2025 · AG · contact PI
Small molecule mimetics of Humanin that normalize neuronal p-Akt as novel therapeutics for AD$639,946
R01 · FY2024 · AG · contact PI
Evaluating the p-Tau inhibition and neuroprotective effects of sAPPalpha using brain permeable small molecules$390,000
R01 · FY2024 · AG · contact PI
Evaluating the p-Tau inhibition and neuroprotective effects of sAPPalpha using brain permeable small molecules$390,000
R01 · FY2023 · AG · contact PI
Small molecule mimetics of Humanin that normalize neuronal p-Akt as novel therapeutics for AD$274,750
RF1 · FY2023 · AG · contact PI
Evaluating the p-Tau inhibition and neuroprotective effects of sAPPalpha using brain permeable small molecules$390,000
R01 · FY2022 · AG · contact PI
Screening for Compounds that Lower Intracellular Alpha-Synuclein Levels$129,915
R21 · FY2022 · AG · contact PI
Small molecule mimetics of Humanin that normalize neuronal p-Akt as novel therapeutics for AD$1,817,118
RF1 · FY2021 · AG · contact PI
Screening for enhancers of secreted clusterin (sCLU) and evaluation in AD models$423,400
R21 · FY2021 · AG · contact PI
Screening for Compounds that Lower Intracellular Alpha-Synuclein Levels$423,400
R21 · FY2021 · AG · contact PI
Screening for SORLA enhancers and evaluation in AD models$429,000
R21 · FY2020 · AG · contact PI
ApoE4-targeted therapeutics that normalize SirT1$472,604
R01 · FY2019 · AG · contact PI
ApoE4-targeted therapeutics that normalize SirT1$297,882
R01 · FY2019 · AG · contact PI
ApoE4-targeted therapeutics that normalize SirT1$472,604
R01 · FY2018 · AG · contact PI
Administrative Supplement for R01AG051386, "ApoE4 Targeted Therapeutic that Normalize SirT1"$250,647
R01 · FY2018 · AG · contact PI
ApoE4-targeted therapeutics that normalize SirT1$472,604
R01 · FY2017 · AG · contact PI
Screening for enhancers of sAPPalpha$192,500
R21 · FY2017 · AG · contact PI
ApoE4-targeted therapeutics that normalize SirT1$476,014
R01 · FY2016 · AG · contact PI
Screening for enhancers of sAPPalpha$231,000
R21 · FY2016 · AG · contact PI
ApoE4-targeted therapeutics that normalize SirT1$512,424
R01 · FY2015 · AG · contact PI
Screening for APPNeo Inhibitors$220,445
R21 · FY2013 · AG · contact PI
Screening for APPNeo Inhibitors$323,443
R21 · FY2012 · AG · contact PI